Literature DB >> 29712745

Impact of Intensive Versus Standard Blood Pressure Management by Tertiles of Blood Pressure in SPRINT (Systolic Blood Pressure Intervention Trial).

Brian P Shapiro1, Walter T Ambrosius2, Joseph L Blackshear3, William C Cushman4, Paul K Whelton5, Suzanne Oparil6, Srinivasan Beddhu7, Jamie P Dwyer8, Lisa H Gren9, William J Kostis10, Michael Lioudis11, Roberto Pisoni12, Clive Rosendorff13, William E Haley14.   

Abstract

Intensive systolic blood pressure (SBP) control improved outcomes in SPRINT (Systolic Blood Pressure Intervention Trial). Our objective was to expand on reported findings by analysis of baseline characteristics, primary outcomes, adverse events, follow-up blood pressure, and medication use differences by baseline SBP (tertile 1 [T1], <132; tertile 2 [T2], 132-145; and tertile 3 [T3], >145 mm Hg). Participants with higher baseline SBP tertile were more often women and older, had higher cardiovascular risk, and lower utilization of antihypertensive medications, statins, and aspirin. Achieved SBP in both treatment arms was slightly higher in T2 and T3 compared with T1 and fewer in the T3 groups achieved SBP targets compared with T1 and T2 groups. The primary composite outcome with intensive versus standard SBP treatment was reduced by 30% in T1, 23% in T2, and 17% in T3 with no evidence of an interaction (P=0.77). Event rates were lower in the intensive arm, and there was no evidence that this benefit differed by SBP tertile. There was no difference in the hazard for serious adverse events in any of the 3 tertiles. Medication utilization differed across the SBP tertiles at baseline with a lesser percentage of diuretics and angiotensin-converting enzyme inhibitors/angiotensin receptor blocker drugs in the higher tertiles-a finding that reversed during the trial. The beneficial effects of intensive SBP lowering were not modified by the level of baseline SBP. Within the parameters of this population, these findings add support for clinicians to treat blood pressure to goal irrespective of baseline SBP.
© 2018 American Heart Association, Inc.

Entities:  

Keywords:  aspirin; blood pressure; follow-up studies; hypertension; risk factors

Mesh:

Substances:

Year:  2018        PMID: 29712745      PMCID: PMC5945323          DOI: 10.1161/HYPERTENSIONAHA.117.10646

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  18 in total

Review 1.  SPRINT: What Remains Unanswered and Where Do We Go From Here?

Authors:  Daniel W Jones; Lyssa Weatherly; John E Hall
Journal:  Hypertension       Date:  2015-11-09       Impact factor: 10.190

2.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors: 
Journal:  JAMA       Date:  2002-12-18       Impact factor: 56.272

3.  The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).

Authors:  Walter T Ambrosius; Kaycee M Sink; Capri G Foy; Dan R Berlowitz; Alfred K Cheung; William C Cushman; Lawrence J Fine; David C Goff; Karen C Johnson; Anthony A Killeen; Cora E Lewis; Suzanne Oparil; David M Reboussin; Michael V Rocco; Joni K Snyder; Jeff D Williamson; Jackson T Wright; Paul K Whelton
Journal:  Clin Trials       Date:  2014-06-05       Impact factor: 2.486

4.  Effect of Intensive Blood Pressure Treatment on Heart Failure Events in the Systolic Blood Pressure Reduction Intervention Trial.

Authors:  Bharathi Upadhya; Michael Rocco; Cora E Lewis; Suzanne Oparil; Laura C Lovato; William C Cushman; Jeffrey T Bates; Natalie A Bello; Gerard Aurigemma; Lawrence J Fine; Karen C Johnson; Carlos J Rodriguez; Dominic S Raj; Anjay Rastogi; Leonardo Tamariz; Alan Wiggers; Dalane W Kitzman
Journal:  Circ Heart Fail       Date:  2017-04       Impact factor: 8.790

Review 5.  Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis.

Authors:  Dena Ettehad; Connor A Emdin; Amit Kiran; Simon G Anderson; Thomas Callender; Jonathan Emberson; John Chalmers; Anthony Rodgers; Kazem Rahimi
Journal:  Lancet       Date:  2015-12-24       Impact factor: 79.321

6.  Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.

Authors: 
Journal:  JAMA       Date:  2000-04-19       Impact factor: 56.272

7.  Generalizability of SPRINT Results to the U.S. Adult Population.

Authors:  Adam P Bress; Rikki M Tanner; Rachel Hess; Lisandro D Colantonio; Daichi Shimbo; Paul Muntner
Journal:  J Am Coll Cardiol       Date:  2015-11-09       Impact factor: 24.094

8.  Influence of Baseline Diastolic Blood Pressure on Effects of Intensive Compared With Standard Blood Pressure Control.

Authors:  Srinivasan Beddhu; Glenn M Chertow; Alfred K Cheung; William C Cushman; Mahboob Rahman; Tom Greene; Guo Wei; Ruth C Campbell; Margaret Conroy; Barry I Freedman; William Haley; Edward Horwitz; Dalane Kitzman; James Lash; Vasilios Papademetriou; Roberto Pisoni; Erik Riessen; Clive Rosendorff; Suzanne G Watnick; Jeffrey Whittle; Paul K Whelton
Journal:  Circulation       Date:  2017-10-11       Impact factor: 29.690

9.  Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease.

Authors:  Eva M Lonn; Jackie Bosch; Patricio López-Jaramillo; Jun Zhu; Lisheng Liu; Prem Pais; Rafael Diaz; Denis Xavier; Karen Sliwa; Antonio Dans; Alvaro Avezum; Leopoldo S Piegas; Katalin Keltai; Matyas Keltai; Irina Chazova; Ron J G Peters; Claes Held; Khalid Yusoff; Basil S Lewis; Petr Jansky; Alexander Parkhomenko; Kamlesh Khunti; William D Toff; Christopher M Reid; John Varigos; Lawrence A Leiter; Dora I Molina; Robert McKelvie; Janice Pogue; Joanne Wilkinson; Hyejung Jung; Gilles Dagenais; Salim Yusuf
Journal:  N Engl J Med       Date:  2016-04-02       Impact factor: 91.245

Review 10.  Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis.

Authors:  Xinfang Xie; Emily Atkins; Jicheng Lv; Alexander Bennett; Bruce Neal; Toshiharu Ninomiya; Mark Woodward; Stephen MacMahon; Fiona Turnbull; Graham S Hillis; John Chalmers; Jonathan Mant; Abdul Salam; Kazem Rahimi; Vlado Perkovic; Anthony Rodgers
Journal:  Lancet       Date:  2015-11-07       Impact factor: 79.321

View more
  4 in total

Review 1.  Sex, Oxidative Stress, and Hypertension: Insights From Animal Models.

Authors:  Jane F Reckelhoff; Damian G Romero; Licy L Yanes Cardozo
Journal:  Physiology (Bethesda)       Date:  2019-05-01

Review 2.  Dangers of Overly Aggressive Blood Pressure Control.

Authors:  Faisal Rahman; John W McEvoy
Journal:  Curr Cardiol Rep       Date:  2018-09-26       Impact factor: 2.931

3.  Heart Failure Prevention in Older Patients Using Intensive Blood Pressure Reduction: Potential Role of Diuretics.

Authors:  Bharathi Upadhya; Laura C Lovato; Michael Rocco; Cora E Lewis; Suzanne Oparil; William C Cushman; John B Kostis; Carlos J Rodriguez; Monique E Cho; Loretta W Cloud; Anjay Rastogi; Clive Rosendorff; Dalane W Kitzman
Journal:  JACC Heart Fail       Date:  2019-12       Impact factor: 12.035

Review 4.  Heart Failure Primary Prevention: What Does SPRINT Add?: Recent Advances in Hypertension.

Authors:  Kirsten Raby; Michael Rocco; Suzanne Oparil; Olivia N Gilbert; Bharathi Upadhya
Journal:  Hypertension       Date:  2021-04-05       Impact factor: 9.897

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.